Readystate Asset Management LP Invests $12.74 Million in Natera, Inc. $NTRA

Readystate Asset Management LP acquired a new position in Natera, Inc. (NASDAQ:NTRA) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 79,155 shares of the medical research company’s stock, valued at approximately $12,742,000. Readystate Asset Management LP owned approximately 0.06% of Natera at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Sound Income Strategies LLC lifted its position in shares of Natera by 95.7% in the third quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock worth $39,000 after purchasing an additional 110 shares in the last quarter. Quent Capital LLC acquired a new position in Natera in the 3rd quarter valued at approximately $46,000. Hilltop National Bank lifted its position in Natera by 59.8% in the 3rd quarter. Hilltop National Bank now owns 310 shares of the medical research company’s stock worth $50,000 after buying an additional 116 shares in the last quarter. N.E.W. Advisory Services LLC lifted its position in Natera by 256.8% in the 2nd quarter. N.E.W. Advisory Services LLC now owns 314 shares of the medical research company’s stock worth $53,000 after buying an additional 226 shares in the last quarter. Finally, Blue Trust Inc. boosted its stake in shares of Natera by 23.1% during the 3rd quarter. Blue Trust Inc. now owns 431 shares of the medical research company’s stock valued at $69,000 after buying an additional 81 shares during the period. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Trading Up 2.4%

NASDAQ:NTRA opened at $211.25 on Wednesday. The firm has a market capitalization of $29.22 billion, a PE ratio of -92.25 and a beta of 1.64. Natera, Inc. has a 1 year low of $125.38 and a 1 year high of $256.36. The firm’s fifty day simple moving average is $229.23 and its 200 day simple moving average is $200.54.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on NTRA. Canaccord Genuity Group reiterated a “buy” rating on shares of Natera in a report on Monday, January 12th. Piper Sandler raised their price target on Natera from $220.00 to $230.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 11th. BNP Paribas Exane upgraded Natera to a “hold” rating and set a $172.00 price target for the company in a report on Monday, October 27th. Citigroup assumed coverage on Natera in a report on Wednesday, January 7th. They issued a “buy” rating and a $300.00 price objective on the stock. Finally, Zacks Research raised shares of Natera from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $249.20.

Insiders Place Their Bets

In related news, insider John Fesko sold 3,594 shares of the business’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $231.02, for a total transaction of $830,285.88. Following the completion of the transaction, the insider owned 178,081 shares of the company’s stock, valued at approximately $41,140,272.62. The trade was a 1.98% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Solomon Moshkevich sold 1,639 shares of the stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $230.77, for a total value of $378,232.03. Following the sale, the insider owned 137,847 shares of the company’s stock, valued at approximately $31,810,952.19. The trade was a 1.18% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 450,787 shares of company stock valued at $105,376,360. 5.63% of the stock is owned by company insiders.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.